Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
Curr Opin Immunol
; 71: 117-123, 2021 08.
Article
en En
| MEDLINE
| ID: mdl-34330018
ABSTRACT
BAFF and APRIL regulate B cell homeostasis by binding to their three receptors BAFFR, BCMA and TACI. The complexity of this system is further increased by shedding of these three receptors; this reduces signaling due to the display of less surface receptors. Further, soluble forms, sBCMA and sTACI, were detected in body fluids and serve as biomarker in malignancies, autoimmune diseases and immunodeficiencies. sBCMA and sTACI function as decoys blocking BAFF and APRIL. BCMA is a promising therapeutic target in multiple myeloma, but sBCMA may reduce therapeutic activity of CAR T cells, bispecific antibodies, and antibody-drug conjugates. Insights into the biochemical mechanism of shedding of BCMA can be harnessed to improve BCMA-directed therapy by blocking its shedding with a γ-secretase inhibitor.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Biomarcadores de Tumor
/
Antígeno de Maduración de Linfocitos B
/
Proteína Activadora Transmembrana y Interactiva del CAML
/
Mieloma Múltiple
Límite:
Humans
Idioma:
En
Revista:
Curr Opin Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2021
Tipo del documento:
Article